Freedom Financial Partners LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,923 shares of the company's stock, valued at approximately $485,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Tallon Kerry Patrick acquired a new position in Johnson & Johnson in the fourth quarter valued at $290,000. Capital & Planning LLC lifted its stake in shares of Johnson & Johnson by 13.6% in the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after purchasing an additional 183 shares during the period. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $85,886,000. Finally, Evernest Financial Advisors LLC lifted its stake in Johnson & Johnson by 3.7% in the fourth quarter. Evernest Financial Advisors LLC now owns 7,861 shares of the company's stock valued at $1,137,000 after buying an additional 280 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ traded up $0.28 during midday trading on Thursday, reaching $153.50. The company's stock had a trading volume of 5,288,204 shares, compared to its average volume of 7,929,037. The stock has a market capitalization of $369.32 billion, a P/E ratio of 23.08, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50 day moving average price of $153.81 and a 200-day moving average price of $153.67. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.
Analysts Set New Price Targets
Several research firms have recently weighed in on JNJ. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Finally, Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $170.88.
Check Out Our Latest Research Report on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
